Bibliography
- National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Colon Cancer. Version 2. 2013. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site
- Chu E. An update on the current and emerging targeted agents in metastatic colorectal cancer. Clin Colorectal Cancer 2012;11(1):1-13
- Prenen H, Vecchione L, Van Cutsem E. Role of targeted agents in metastatic colorectal cancer. Target Oncol 2013;8(2):83-96
- Zaltrap [prescribing information]. Regeneron Pharmaceuticals, Inc./sanofi-aventis U.S. LLC; Bridgewater, NJ: 2012
- National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Colon Cancer. Version 2. 2012. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site
- Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to FOLFIRI improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin–based regimen. J Clin Oncol 2012;30:3499-506
- Bennouna J, Sastre J, Arnold D, et al. ML18147 Study Investigators. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013;14:29-37
- Saltz L. Colorectal cancer treatments and therapy innovations. Cancernetwork 2013. Available from: http://www.cancernetwork.com/colorectal-cancer/content/article/10165/2143619
- Allegra CJ, Lakomy R, Tabernero J, et al. Effects of prior bevacizumab (B) use on outcomes from the VELOUR study: a phase III study of aflibercept (Afl) and FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin regimen. J Clin Oncol 2012;30(Suppl):abstract 3505
- Chu QS. Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors. Expert Opin Biol Ther 2009;9:263-71
- Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62
- Loges S, Schmidt T, Carmeliet P. “Antimyeloangiogenic” therapy for cancer by inhibiting PlGF. Clin Cancer Res 2009;15:3648-53
- Escudero-Esparza A, Martin TA, Davies ML, Jiang WG. PGF isoforms, PlGF-1 and PGF-2, in colorectal cancer and the prognostic significance. Cancer Genomics Proteomics 2009;6:239-46
- Kopetz S, Hoff PM, Morris JS, et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 2010;28:453-9
- Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 2012;15:171-85
- Yu L, Liang XH, Ferrara N. Comparing protein VEGF inhibitors: in vitro biological studies. Biochem Biophys Res Commun 2011;408:276-81
- Zaltrap. Summary of product characteristics. European Medicines Agency; Sanofi; Paris, France: 2013
- Avastin [prescribing information]. Genentech, Inc; South San Francisco, CA: 2013